デフォルト表紙
市場調査レポート
商品コード
1086999

コンパニオン診断(CDx):市場予測(2022年~2027年)

Companion Diagnostics (CDx) Market - Forecasts from 2022 to 2027

出版日: | 発行: Knowledge Sourcing Intelligence | ページ情報: 英文 121 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
コンパニオン診断(CDx):市場予測(2022年~2027年)
出版日: 2022年04月14日
発行: Knowledge Sourcing Intelligence
ページ情報: 英文 121 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界のコンパニオン診断(CDx)の市場規模は、2020年に56億3,700万米ドルとなり、17.68%のCAGRで推移し、2027年までには176億1,800万米ドルに達すると予測されています。

市場の成長を促進すると予測される主な理由は、慢性疾患の有病率が上昇し、コンパニオン診断(CDx)の市場導入が進んでいることです。さらに、生活水準の向上と技術の利用可能性に伴う医療費の増加や、精密医療への需要と相まって、コンパニオン診断(CDx)機器に顕著なビジネスチャンスがもたらされています。

当レポートでは、世界のコンパニオン診断(CDx)市場を調査し、市場規模や予測、市場の促進要因および課題、市場動向、設置タイプ別・車両タイプ別・地域別の市場分析、競合情勢、主要企業のプロファイルなどの体系的な情報を提供しています。

目次

第1章 イントロダクション

  • 市場の定義
  • 市場セグメンテーション

第2章 調査手法

  • 調査データ
  • 前提条件

第3章 エグゼクティブサマリー

  • 調査のハイライト

第4章 市場力学

  • 市場促進要因
  • 市場抑制要因
  • ポーターのファイブフォース分析
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • 業界のバリューチェーン分析

第5章 コンパニオン診断(CDX)市場:技術別

  • イントロダクション
  • ポリメラーゼ連鎖反応(PCR)
  • 免疫組織化学(IHC)
  • インサイチュハイブリダイゼーション(ISH)
  • 次世代シーケンシング(NGS)

第6章 コンパニオン診断(CDX)市場:適応症別

  • イントロダクション
  • 肺がん
  • 乳がん
  • 大腸がん
  • その他

第7章 コンパニオン診断(CDX)市場:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 南米
    • ブラジル
    • アルゼンチン
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • その他
  • 中東・アフリカ
    • サウジアラビア
    • イスラエル
    • その他
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他

第8章 競合環境と分析

  • 主要企業と戦略分析
  • 新興企業と市場の収益性
  • 合併、買収、合意、およびコラボレーション
  • ベンダー競争力マトリックス

第9章 企業プロファイル

  • Abbott
  • Aglient Technolgies Inc.
  • Arup Laboratories
  • F. Hoffmann-La Roche Ltd
  • Illumina, Inc.
  • Invivoscribe, Inc
  • Myriad Genetics, Inc.
  • QIAGEN
  • Thermo Fisher Scientific Inc.
目次
Product Code: KSI061611889

The companion diagnostics (CDx) market is projected to witness a compound annual growth rate of 17.68% to grow to US$17.618 billion by 2027, from US$5.637 billion in 2020.

A companion diagnostic device is a medical device that enables the user to receive crucial information regarding the use of corresponding drugs or biological products. The prime reason which is forecasted to drive the market growth is the rising prevalence of chronic diseases which has increased the market adoption of companion diagnostics. Furthermore, increasing healthcare expenditure with the rise in the standard of living and availability of technology coupled with demand for precision medicine has created notable opportunities for the companion diagnostic device.

Based on geography, the companion diagnostics (CDx) market is segmented into North America, South America, Europe, the Middle East and Africa, and the Asia Pacific. The Asia Pacific region is forecasted to hold a substantial share of the market owing to a surge in medical tourism and advancement in the medical sector. The North American and European regions are projected to hold the largest share of the market with an increase in healthcare spending.

A next-generation sequencing companion diagnostic is expected to hold a notable share of the market.

Based on technology, the companion diagnostic market can be distinguished as a polymerase chain reaction, immunohistochemistry, in-situ hybridization, and next-generation sequencing. A next-generation sequencing companion diagnostic is expected to hold a significant share of the market, owing to technological effectiveness and better market prospects.

Lung and Breast Cancer indication is expected to dominate the market for a companion diagnostic.

By indication, the companion diagnostic market can be segmented into lung cancer, breast cancer, colorectal cancer, and others. Lung and breast cancer indication is expected to dominate the companion diagnostic market, owing to a higher number of cases. Lung and breast cancer are the two most prevalent types of cancers. These two are also the form of cancers with the highest number of deaths. A report published by the World Health Organization (WHO) shows that in 2020, there were 2.26 million cases of breast cancer, while 2.21 million cases of lung cancer. Breast cancer caused 685 thousand deaths in 2020, while lung cancer killed 1.80 million people. The growing prevalence of these forms of cancers is expected to create significant demand for a companion diagnostic.

Growth Factors

  • Rising cases of cancer

One of the prime reasons supporting the growth in the companion diagnostics (CDx) market is the surging cancer cases. Companion diagnostic notably helps in cancer diagnostic and treatment. The device facilitates identifying a specific therapeutic solution for an individual suffering from cancer. A rise in cancer cases is expected to drive notable demand for companion diagnostic devices. Data from National Cancer Institute, NIH shows that 1.806 million new cases of cancer were diagnosed in the United States in 2020, increasing the rate of new cancer cases to 442.4% per 100,000 people. The rise in cancer cases is expected to surge the demand for diagnostic and treatment, hence supporting the market for a companion diagnostic.

  • The surge in healthcare expenditure

Another key factor that supports the market for companion diagnostics (CDx) is a surge in healthcare expenditure with the rise in the standard of living and the adoption of advanced medical technology. Data from The World Bank shows that global per capita healthcare expenditure has been increasing at a remarkable rate. Per capita healthcare expenditure reached US$1,110.286 in 2018 from US$1,020.88 in 2016. Promising investment in the industry is expected to expand the market prospects further. In the US, for instance, healthcare expenditure is expected to grow at a CAGR from 2019 to 2028 and is expected to reach US$6.2 trillion by 208, from US$4.1 trillion in 2020. It is expected to invest in the healthcare industry and is projected to provide exceptional growth opportunities.

COVID Insights

The coronavirus pandemic resiliently impacted the market for a companion diagnostic. The surge in cases and the emergency situation created by the robust spread of the COVID-19 led to more fund investment towards the vaccination and hence impacted the market for a companion diagnostic. Furthermore, fear of catching the virus refrained patients from going for regular checks, which impacted the discovery of new or potential cases and affected the market prospects.

Key Development

  • April 2021, Approval. The FDA gave a green signal to the country's first-ever companion diagnostic device developed especially for endometrial cancer diagnosis, innovated by Roche. Ltd. The VENTANA MMR RxDx Panel developed by the latter successfully identifies endometrial cancer and helps in its treatment. Annually, around 90 thousand women die due to endometrial cancer. The companion diagnostic developed by Roche can identify the patient's eligibility for JEMPERLI monotherapy.

Market Segmentation:

  • By Technology

Polymerase Chain Reaction (PCR)

Immunohistochemistry (IHC)

In-situ Hybridization (ISH)

Next-Generation Sequencing (NGS)

  • By Indication

Lung Cancer

Breast Cancer

Colorectal Cancer

Others

  • By Geography

North America

  • USA
  • Canada
  • Mexico

South America

  • Brazil
  • Argentina
  • Others

Europe

  • Germany
  • France
  • United Kingdom
  • Italy
  • Others

Middle East and Africa

  • Saudi Arabia
  • Israel
  • Others

Asia Pacific

  • China
  • India
  • Japan
  • South Korea
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. COMPANION DIAGNOSTICS (CDX) MARKET, BY TECHNOLOGY

  • 5.1. Introduction
  • 5.2. Polymerase Chain Reaction (PCR)
  • 5.3. Immunohistochemistry (IHC)
  • 5.4. In-situ Hybridization (ISH)
  • 5.5. Next-Generation Sequencing (NGS)

6. COMPANION DIAGNOSTICS (CDX) MARKET, BY INDICATION

  • 6.1. Introduction
  • 6.2. Lung Cancer
  • 6.3. Breast Cancer
  • 6.4. Colorectal Cancer
  • 6.5. Others 

7. COMPANION DIAGNOSTICS (CDX) MARKET, BY GEOGRAPHY 

  • 7.1. Introduction 
  • 7.2. North America
    • 7.2.1. USA
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others 
  • 7.4. Europe
    • 7.4.1. Germany
    • 7.4.2. France
    • 7.4.3. United Kingdom
    • 7.4.4. Italy
    • 7.4.5. Others 
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. Israel
    • 7.5.3. Others
  • 7.6. Asia Pacific 
    • 7.6.1. China
    • 7.6.2. India
    • 7.6.3. Japan
    • 7.6.4. South Korea
    • 7.6.5. Others 

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Emerging Players and Market Lucrativeness
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Vendor Competitiveness Matrix

9. COMPANY PROFILES

  • 9.1. Abbott
  • 9.2. Aglient Technolgies Inc.
  • 9.3. Arup Laboratories
  • 9.4. F. Hoffmann-La Roche Ltd
  • 9.5. Illumina, Inc.
  • 9.6. Invivoscribe, Inc
  • 9.7. Myriad Genetics, Inc.
  • 9.8. QIAGEN
  • 9.9. Thermo Fisher Scientific Inc.